Dengue is an expanding public health problem, and an effective vaccine remains elusive. This review discusses how the significant influence of sequential infection with different dengue virus serotypes on the severity of disease can be viewed in terms of beneficial and detrimental effects of heterologous immunity. A more complete understanding of these effects is likely to be critical for predicting optimal vaccine-induced immune responses.
Dengue is an expanding public health problem, and an effective vaccine remains elusive. This review discusses how the significant influence of sequential infection with different dengue virus serotypes on the severity of disease can be viewed in terms of beneficial and detrimental effects of heterologous immunity. A more complete understanding of these effects is likely to be critical for predicting optimal vaccine-induced immune responses.

Among scientists in the developed world, there has been a recent resurgence of interest in exotic diseases, with the aim of protecting the global population from emerging infectious disease threats. The renewed commitment of effort and resources has welcomed implications for the developing world, whose population faces the greatest part of these threats. Among the biological threats considered most serious are the viral hemorrhagic fevers. Although this term usually brings to mind the deadly outbreaks of Ebola virus, in reality over 99% of the cases of viral hemorrhagic fever reported worldwide are related instead to dengue hemorrhagic fever (DHF) (1).

DHF is caused by the dengue viruses (DENVs), members of the Flaviviridae family of small enveloped viruses (2). The flaviviruses carry a single-stranded RNA genome of relatively simple organization. A single open reading frame in the RNA directs the synthesis of a single polyprotein that is processed by viral and host cell proteases to produce the ten viral proteins, including three structural proteins (core [C]; membrane [M], produced as a precursor protein; and envelope [E]) and seven nonstructural (NS) proteins (Figure 1). The DENV complex encompasses four closely related serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. All four DENV serotypes are transmitted between humans in nature by mosquitoes of the genus Aedes, principally Aedes aegypti, which is highly domesticated and has a preference for biting humans.

It has been estimated that over 50 million DENV infections occur globally each year (3). Most of these infections are clinically inapparent. Among symptomatic cases, the majority of subjects experience uncomplicated dengue fever (DF), an acute febrile illness typically lasting 3–7 days, accompanied by headache, myalgias, and, less often, a maculopapular rash. The headache and myalgias may be quite debilitating, which originated the name “break-bone fever” that was recorded prior to the 1900s (4). Laboratory findings in patients with DF include leucopenia thrombocytopenia, and mild elevations in serum hepatic transaminases (5). Fatigue may be prolonged for months after resolution of fever, but patients eventually recover without sequelae. None of these features is sufficiently specific for accurate clinical diagnosis of DF. Laboratory support for detection of IgM antibody or virus (by RT-PCR or virus isolation) is therefore important for recognition of outbreaks.

DHF represents the severe clinical manifestation of DENV infection, which occurs in no more than 3% of infected individuals (6). Fever, headache, and myalgias are prominent symptoms in DHF, as they are in DF. DHF is distinguished from DF on clinical grounds, with the three primary criteria being the occurrence of a vascular permeability defect resulting in plasma leakage; multifactorial hemostatic abnormalities, including marked thrombocytopenia; and a bleeding diathesis (7). Plasma leakage is evidenced by hemocencentration and/or effusions in the pleural or peritoneal spaces, which usually occur after 3–5 days of fever, near the time of defervescence. When severe, the plasma leakage leads to hypotension and circulatory collapse, and this is the most important concern for triage and therapy. Thrombocytopenia is quite severe in DHF, with a platelet count of less than 100,000 cells/mm³ required to fulfill the case definition. The nadir of the platelet count is typically coincident with plasma leakage, and severe thrombocytopenia also occurs in a significant percentage of patients with DF; nevertheless, the decline in platelet count typically precedes plasma leakage, and this finding has been useful in deciding whether to hospitalize patients suspected to have DHF (8). Bleeding manifestations, for example, from the gastrointestinal tract, can be severe in patients with DHF but are not usually severe enough to require transfusion and are rarely the principal cause of hypotension. Despite the use of the term “hemorrhagic fever,” many patients with DHF have minor hemorrhagic manifestations; often the occurrence of petechiae elicited by inflation of a blood pressure cuff on the arm for 5 minutes (the “tourniquet test”) is the only clinical sign.

The emergence of DHF as a global infectious disease threat is striking in its persistence and magnitude. Southeast Asia and the western Pacific region, where DHF was first recognized as a clinical entity, have faced this health problem for almost 50 years. Nevertheless, during each decade the number of DHF cases, the number of countries affected, and the geographic distribution of DHF have all increased steadily (3). DHF is, in comparison, a new problem in the tropical Western hemisphere, but one that has rapidly expanded in scope. Although essentially absent from the area prior to 1981, DHF has during the past decade been seen throughout Latin America and the Caribbean. It is currently estimated that over 3 billion individuals live in areas at risk for DHF and that hundreds of thousands of cases and thousands of deaths due to DHF occur each year, representing an urgent health problem to be addressed. Human activities that have led to enhanced mosquito breeding capacity, increased interaction between mosquitoes and humans, and increased dispersal of viruses in both mosquito and human hosts have contributed (and continue to contribute) to the emer-

Nonstandard abbreviations used: antibody-dependent enhancement of infection (ADE); core (C); dengue fever (DF); dengue hemorrhagic fever (DHF); dengue virus (DENV); envelope (E); membrane (M); nonstructural (NS).

Conflict of interest: The author has declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 113:946–951 (2004).

doi:10.1172/JCI200421512.
have also taken advantage of
http://www.jci.org Volume 113 Number 7 April 2004
947

Unlike the situation with HIV and hepatitis C virus, DENV does
range they commanded prior to the yellow fever eradication efforts
1970s and have re-established essentially the full geographical
lapse in mosquito control efforts that has occurred since the
In principle, an effective vaccine against DENV is highly feasible.
Background of dengue vaccine development

Figure 1
Organization of the flavivirus genome and its resulting proteins and the
location of the major targets of the immune response. The DENV
genome is a single-stranded sense RNA with a single open reading
frame (ORF; top). The ORF is translated as a single polyprotein (middle)
that is cleaved by viral and host proteases to yield the ten viral prote-
ins: the C protein; the M protein, which is synthesized as the larger
precursor protein pre-M (pM); the major E glycoprotein; and seven NS
proteins involved in viral replication among other functions (bottom). The
strength of the antibody and T cell responses to individual viral proteins
is indicated below.

gence of DHF, as discussed in several recent reviews (9, 10). Poorly
planned development has been a major factor, especially in urban
centers of the developing world. The attendant inadequate sanita-
tion and potable water supply, leading to an increase in mosquito
breeding places, and the concentration of susceptible human hosts
in close proximity to the mosquitoes also facilitate transmission.
In the Western hemisphere, A. aegypti have also taken advantage of
the lapse in mosquito control efforts that has occurred since the
1970s and have re-established essentially the full geographical
range they commanded prior to the yellow fever eradication efforts
of the mid-twentieth century.

At present, there is no specific therapy available for DHF. Approp-
rate fluid management to correct hypovolemia has been suc-
cessful in reducing the mortality of DHF (7, 11, 12), but access to
medical services remains problematic in many developing coun-
dies. Mosquito control, which is costly and often ineffective,
remains the only method of preventing DHF currently available.
Development of an effective vaccine against DENVs has therefore
been considered a high priority by the WHO.

Background of dengue vaccine development
In principle, an effective vaccine against DENV is highly feasible.
Unlike the situation with HIV and hepatitis C virus, DENV does
not cause chronic infection. Viral replication is effectively con-
trolled after a short (3- to 7-day) period of viremia, and individuals
who have recovered from DENV infection are immune to rechal-
lenge (13). Studies conducted in the 1940s demonstrated that a
DENV strain derived by serial propagation in suckling mouse brain
was attenuated in humans and could elicit protective immunity
against DENV challenge (13).

There are a number of candidate DENV vaccines currently in
development (Table 1) (14). Live attenuated strains of all four
DENV serotypes have been derived by the traditional approach of
serial propagation in primary dog or monkey kidney cells (15–17).
This effort has been slowed by the lack of an animal model or in
vitro markers of attenuation in humans. Improved molecular viro-
logy techniques and an improved understanding of the genomic
structure of DENV have permitted a more rapid approach based
on engineering of attenuating mutations into infectious cDNA
clones of each of the four DENV serotypes, with the added theo-
retical advantage of a lower possibility of reversion to virulence
(18–20). Another molecular approach being utilized is the creation
of four separate infectious chimeric flaviruses, each of which con-
tains the pre-M and E genes of one of the four DENV serotypes in
a single “backbone” containing the C and NS proteins of an atten-
uated flavivirus, either the yellow fever vaccine strain or an attenu-
ated DENV strain (21, 22). DNA vaccines consisting of plasmids
expressing one or a few proteins from each DENV serotype are in
an earlier stage of development, as are subunit vaccines based on
purified recombinant DENV proteins (23, 24). Several of these
approaches have demonstrated protective efficacy in animal mod-
els of DENV infection, and a few have shown safety and immuno-
genicity in early phase clinical studies (14, 18, 25, 26).

Two main obstacles have delayed further clinical development of
these candidate vaccines. First, an effective vaccine needs to prevent
infection with all four DENV serotypes. Natural DENV infection
induces long-lasting protective immunity only to the same serotype
and only short-term (months) protection from infection with other
serotypes (13). Although live attenuated and recombinant vaccines
to all four DENV serotypes have been developed, incorporation of
these into a tetravalent formulation that retains the immunogenic-
ity of all four components has proven difficult, requiring the use of
more complicated, multiple-dose immunization regimens (25).

The second and more significant obstacle is the current inability
to predict whether candidate DENV vaccines will be at all effective
in preventing DHF. DHF was unrecognized prior to the late 1950s.
Therefore, the experimental challenge studies in humans conduct-
during and shortly after World War II did not attempt to test the
efficacy of candidate vaccines against DHF. Subsequent studies of
candidate vaccines have analyzed efficacy only in experimental ani-

Table 1
Immunological considerations and current status in development of candidate dengue vaccines

<table>
<thead>
<tr>
<th>No. of dengue antigens included</th>
<th>Live attenuated</th>
<th>Chimeric virus</th>
<th>Plasmid DNA</th>
<th>Subunit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All (10)</td>
<td>2 (10 for viral “backbone” only)</td>
<td>No</td>
<td>Usually 1</td>
</tr>
<tr>
<td>In vivo replication</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Elicits T and B cell memory</td>
<td>Best</td>
<td>Best</td>
<td>Excellent</td>
<td>Poor: Th, B, Poor: CTL</td>
</tr>
<tr>
<td>Anticipated durability of immune response</td>
<td>Best</td>
<td>Best</td>
<td>Good</td>
<td>Usually poor</td>
</tr>
<tr>
<td>Protective in animal models</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Status of vaccine development</td>
<td>Phase I/II</td>
<td>Phase I/II</td>
<td>Preclinical</td>
<td>Preclinical</td>
</tr>
</tbody>
</table>

Immune responses to DENV

The principal targets of the immune response to DENV are illustrated in Figure 1. The E glycoprotein is the principal component of the external surface of the DENV virion (27) and is a dominant target of the response consisting of antibodies against DENV. Antibodies against E have been shown to inhibit viral binding to cells and to neutralize viral infectivity in vitro (28). Passive transfer of antibodies against E protected mice from DENV challenge (29). Antibodies against E show variable degrees of cross-reactivity among the DENV serotypes, although neutralization of infectivity by antibodies is usually more serotype specific than virion binding (28). Binding of antibody to virus at non-neutralizing epitopes, or at concentrations below the neutralization endpoint, can enhance the uptake of virions into mononuclear cell lines and primary human monocytes in vitro through interaction with cell surface Ig receptors, a phenomenon known as antibody-dependent enhancement of infection (ADE) (30). These “enhancing” antibodies do not increase infection of human DCs, which are highly permissive to DENV infection, however (31, 32).

While not a component of the virion, the NS1 protein is also an important target of antibodies against DENV. NS1 is expressed on the surface of infected cells and is also secreted into the circulation as a soluble multimer (33). Antibodies against NS1 can trigger complement-mediated lysis of DENV-infected cells in vitro and have been shown to protect mice from DENV challenge (34). A monoclonal antibody directed against the pre-M protein has also been shown to protect mice from DENV challenge (35); however, the mechanism of this protection and its relevance to natural protective immunity are uncertain.

As with other viruses, the CD4+ and CD8+ T cell response to DENV is directed against multiple viral proteins (Figure 1), although the NS3 protein appears to be particularly immunogenic, with a preponderance of the T cell epitopes identified (36, 37). DENV-reactive T cells vary in their ability to recognize different DENV serotypes, depending upon the degree of homology at a given epitope. However, cross-reactivity with multiple serotypes is common, especially at epitopes in the more highly conserved NS proteins (38, 39). DENV-reactive CD4+ and CD8+ T cells predominantly produce high levels of IFN-γ as well as TNF-α, TNF-β, and chemokines including macrophage inhibitory protein-1β upon interaction with DENV-infected antigen presenting cells, and are efficient at lysis of DENV-infected cells in vitro (39, 40).

The extent to which these immune responses contribute to the long-term protective immunity afforded by natural primary DENV infection has not been fully defined. Symptomatic DENV infections, including cases of DHF, can occur despite the presence of antibodies capable of neutralizing in vitro infection of epithelial cell lines (41, 42). Neutralization of infection in mononuclear cells (instead of enhancement of infection) may be more strongly associated with protection from DHF (41), although this association has been reported in only one study. There is very little published information on the association of specific T cell responses with protection. However, broadly serotype–cross-reactive IFN-γ production in vitro showed a weak association with mild disease in a small study cohort (43).

Evidence of an immunological basis for DHF

The principal mechanisms by which DENV infection causes DHF have been a subject of controversy from the time the syndrome was first recognized. Opposing views have focused on the effect of viral and host factors on disease severity (44, 45).

Differences in virulence between naturally circulating DENV strains had been suspected based on differences in clinical profiles observed during isolated DENV outbreaks in Indonesia and the Pacific Islands (46, 47). More recently, studies in Peru and Sri Lanka have provided more convincing data, demonstrating the association of DHF with specific viral genotypes and not with others (48–50). Specific genetic determinants potentially explaining this association have been mapped to the E gene and to the 5′ and 3′ untranslated regions of the DENV genome (51–53). However, in the absence of a validated model of virulence in humans, it has not been possible to verify that these genetic elements are responsible for virulence or to confirm any proposed mechanism for virulence.

Key seroepidemiological studies by Halstead and colleagues in Thailand during the 1960s first suggested an association of increased risk for DHF with a secondary DENV infection; that is, a new DENV infection in an individual who had previously experienced one or more DENV infections (54, 55). This hypothesis has since received strong confirmation from the “experiment of nature” in a large outbreak of DHF associated with DENV-2 in Cuba (56), as well as several independent prospective cohort studies in Southeast Asia (57–59). These observations have provided the basis for exploration of the possibility of a pathologic role for the immune response to DENV in the development of DHF. Age, race/ethnicity, nutritional state, and underlying chronic diseases such as asthma have also been suggested to contribute to DHF risk, although the data supporting these associations are weaker and the mechanisms involved are poorly defined.

Antibodies against DENV can affect the course of disease through multiple mechanisms (Table 2). Passive transfer of antibody against DENV did increase viremia titers in nonhuman primates in one study (60), and recent studies have demonstrated a positive correlation between peak viremia titer and disease severity in humans (61, 62), supporting the idea of the potential in vivo importance of ADE. The occurrence of DHF during primary DENV infection in the first year of life in children born to DENV-immune mothers, and who therefore acquire antibody against DENV transplacentally, also supports the idea of an in vivo role for ADE (63). However, high viremia titers in older children and adults with primary DENV infections and in clinically mild secondary DENV infections indicate that other factors are involved (64, 65). Immune complex formation in vivo has been detected in association with complement activation in patients with severe disease (66). Cross-reactivity of antibodies against E with plasminogen has been associated with bleeding in acute DENV infection, although not with DHF (67).

Cytokine production and cytolysis by activated T lymphocytes are additional potential contributors to disease (Table 2). Elevations of circulating levels of activation markers including soluble TNF receptors, soluble IL-2 receptors, and soluble CD8 have been shown to correlate with disease severity (61, 68–71). Similar associations with disease severity have been shown for the expression of activation markers on circulating CD8+ T cells (72) and the expansion of DENV epitope–specific T cell populations (73, 74). Increased production of various cytokines, including IFN-γ, TNF-α, IL-10, and chemokines has also been detected in acute DENV infection (69–71, 75–77). Although elevations in both type 1 and type 2 cytokine lev-
els are detected in DHF, the timing of their production appears to be an important factor with earlier induction of type 1 cytokines being associated with more severe disease (61). Analysis of T cell responses to DENV prior to secondary DENV infections showed an association between in vitro TNF-α responses to DENV antigens and more severe disease during the subsequent infection (43).

**Heterologous immunity and the pathogenesis of DHF**

Although similar response mechanisms appear to operate in both protective and pathological immunity to DENV, a principal immunological consideration is the heterologous nature of secondary DENV infection. The DENV causing secondary disease is always of a different serotype than the virus that induced immune responses during the earlier DENV infection, and therefore the antibodies and memory T lymphocytes induced by the primary DENV infection typically encounter antigens that differ (although some may be the same) in sequence from their original target antigen. The magnitude of these sequence differences is epitope dependent, but all sequence differences have the potential to affect the quality of the effector response and also modify the immunological repertoire. We speculate that the immune response to these heterologous sequences has the net effect of altering the balance between a protective and pathological outcome.

The effect of sequence differences at antibody-binding sites is to reduce the avidity of the interactions between the pre-existing antibodies and the new DENV serotype. These less avid interactions have a significant effect on the ability of the antibodies to neutralize virus infectivity. However, there is sufficient binding of antibody to the virion to trigger ADE. In addition, these low-avidity antibodies increase in titer in preference to new antibodies with high avidity for the new DENV serotype, because the pre-existing memory B cells and plasma cells are more rapidly activated than naive B cells. The pattern of antibody responses in convalescence, therefore, is influenced heavily by the serotype of the primary DENV infection, a phenomenon referred to as “original antigenic sin” (78).

The effect of sequence differences at T cell epitopes is more complex, consistent with the wider range of effector functions of T cells. Variant peptides, or altered peptide ligands, induce different activation signals in antigen-specific T lymphocytes and thereby modulate specific effector functions of CD4+ and CD8+ T cells (79, 80). In general, such partial T cell agonists have the greatest effect on the proliferation responses and less effect on cytotoxicity responses. Some partial T cell agonists fail to induce cytokine production, whereas others induce an altered cytokine response profile. We have observed just such effects in the in vitro responses of DENV-reactive T cells to peptides of heterologous DENV serotypes (81). Furthermore, a phenomenon analogous to “original antigenic sin” would be expected to occur in the T cell response to secondary DENV infections, in which expansion of the pre-existing lower avidity memory T cell populations takes precedence over the expansion of naive T cell populations with higher avidity for the new DENV serotype. Recent studies of the T cell repertoire after secondary DENV infection support this view (74).

The potential importance of heterologous immunity in influencing the severity of DENV disease is bolstered by data from an animal model of sequential virus infections. In this experimental system, previous infection with one virus (e.g., lymphocytic choriomeningitis virus) altered the response to a subsequent vaccinia virus challenge, altering the hierarchy of epitope-specific T cell responses and resulting in lower virus titers but greater tissue

**Table 2**

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Postulated effect(s)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td>Increased cellular infection, increased viral burden</td>
<td>(45, 60, 84)</td>
</tr>
<tr>
<td></td>
<td>Complement activation</td>
<td>(66, 85, 86)</td>
</tr>
<tr>
<td>Cross-reactivity to coagulation and endothelial cell proteins</td>
<td>Bleeding, endothelial cell dysfunction</td>
<td>(67, 87, 88)</td>
</tr>
<tr>
<td>T lymphocytes</td>
<td>Increased vascular permeability</td>
<td>(61, 68, 69)</td>
</tr>
<tr>
<td></td>
<td>Hepatic injury</td>
<td>(40)</td>
</tr>
</tbody>
</table>

**Figure 2**

Proposed model of heterologous immunity in secondary dengue virus infections and its implications for the pathogenesis of dengue hemorrhagic fever. Primary DENV-2 infection and sequential DENV-1 and DENV-2 infections are compared for illustration purposes. The naive T cell repertoire (pale colors) likely contains some cells with higher avidity for DENV-1 than DENV-2 (red; DENV-1 > DENV-2) and other cells with higher avidity for DENV-2 than DENV-1 (blue; DENV-2 > DENV-1). During primary infection, T cell populations with higher avidity for the infecting serotype are preferentially expanded and enter the memory pool (shown as darker colors). When DENV-2 infection follows DENV-1 infection, the memory T cell populations with higher avidity for the earlier infection expand more rapidly than do naive T cell populations. Because these DENV-1–specific memory T cells have lower avidity for DENV-2, viral clearance mechanisms are suboptimal, whereas proinflammatory responses contribute to disease.
inflammation (82, 83). A model for the effect of heterologous immunity in the pathogenesis of DHF is shown in Figure 2. We postulate that the low-avidity T cells that dominate the response to secondary DENV infections are less than optimally efficient at elimination of DENV-infected cells and that the pattern of cytokine production is altered such that proinflammatory cytokine production (e.g., TNF-α) is enhanced and antiviral cytokine production (e.g., IFN-γ) is reduced. These effects could combine to induce the plasma leakage symptomatic of DHF.

**Responding to the challenge**

To maximize protection and minimize pathologic heterologous immunity and achieve long-lasting immune responses, an optimal vaccine to prevent DENV infections including DENV should induce high-avidity antibodies and T lymphocytes against all four DENV serotypes. The theoretical advantages of live attenuated vaccines or plasmid DNA vaccines (Table 1) have placed them on a faster track toward clinical development. Tetravalent attenuated vaccines or plasmid DNA vaccines (Table 1) have placed them on a high-avidity antibodies and T lymphocytes against all four DENV vaccine to prevent DENV infections including DHF should induce high-avidity antibodies and T lymphocytes against all four DENV serotypes. The theoretical advantages of live attenuated vaccines or plasmid DNA vaccines (Table 1) have placed them on a faster track toward clinical development. Tetravalent attenuated vaccines have been developed, but researchers have encountered problems in finding a formulation that balances the immunogenicity of all four viruses (25). Recombinant chimeric flavivirus vaccines show promise in induction of antibodies against E (21), but it will be important to determine whether the common epitopes in the NS proteins of the viral “backbone” will induce optimal T cell responses. Some findings suggest that individuals with mild and severe disease target different epitopes in their T cell response to DENV (73). Nucleotide sequences from different DENVs could theoretically be introduced into a single vaccine “backbone” to provide the most favorable targets for a high-avidity, cross-serotype immune response. Much additional research is needed to identify and characterize protective and pathologic immune responses in order to make an effective DENV vaccine a reality.

**Address correspondence to:** Alan L. Rothman, Center for Infectious Disease and Vaccine Research, Room S5-326, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655, USA. Phone: (508) 856-4182; Fax: (508) 856-4890; E-mail: alan.rothman@umassmed.edu.